Graybug Vision to Participate in the American Academy of Ophthalmology 2021 Annual Meeting
November 01 2021 - 7:30AM
Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage
biopharmaceutical company focused on developing transformative
medicines for the treatment of diseases of the retina and optic
nerve, today announced two clinical data presentations at the
American Academy of Ophthalmology (AAO) 2021 Annual Meeting to be
held on November 12-15, 2021 in New Orleans, Louisiana, as well as
a company presentation at the Eyecelerator@AAO 2021 event on
November 11, 2021:
- Fred Guerard, PharmD, Chief Executive Officer
of Graybug Vision, to present company overview as part of Retina
Showcase at Eyecelerator@AAO 2021 on November 11, 2021, at 2:50
p.m. ET / 1:50 p.m. CT / 11:50 a.m. PT, followed by a panel
discussion.
- Arshad Khanani, MD, MA, to
present scientific E-Poster titled “Safety and Durability of
Intravitreal Sunitinib Malate Depot (GB-102) in Wet Age-Related
Macular Degeneration (ALTISSIMO, Phase 2b Trial)”. AAO attendees
will be able to view E-Poster any time the Exhibit Hall is open
from November 12-15. E-Poster will be available for viewing on AAO
website after the Annual Session.
- Veeral Sheth,
MD, to present late breaker titled
“Intravitreal Sunitinib Malate Depot (GB-102): Durability and
Safety in Wet Age-Related Macular Degeneration (ALTISSIMO, Phase
2B)” at AAO Retina Subspecialty Day on November 13, 2021, at 10:02
a.m. ET / 9:02 a.m. CT / 7:02 a.m. PT.
About Graybug
Graybug is a clinical-stage biopharmaceutical company focused on
developing transformative medicines for the treatment of diseases
of the retina and optic nerve. The company’s proprietary ocular
delivery technologies are designed to maintain effective drug
levels in ocular tissue for six months and potentially longer,
improving disease management, reducing healthcare burdens and
ultimately delivering better clinical outcomes. Graybug’s lead
product candidate, GB-102, a formulation of the pan-vascular
endothelial growth factor (VEGF) inhibitor, sunitinib malate
targeting a six-month or longer dosing regimen, inhibits multiple
neovascular pathways for the intravitreal treatment of retinal
diseases, including wet age-related macular degeneration. Graybug’s
other product candidates developed using its proprietary
technologies also include GB-401, an injectable sustained-release
formulation of a beta-adrenergic blocker prodrug, for primary
open-angle glaucoma, with a dosing regimen of once every six months
or longer. Founded in 2011 on the basis of technology licensed from
the Johns Hopkins University School of Medicine, Graybug has
offices in Redwood City, California and in Baltimore, Maryland. For
more information, please visit www.graybug.vision.
Investor
ContactIR@graybug.vision(650) 487-2409 |
Media
Contactmedia@graybug.vision(404) 384-0067 |
Graybug Vision (NASDAQ:GRAY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Graybug Vision (NASDAQ:GRAY)
Historical Stock Chart
From Jul 2023 to Jul 2024